Nuvation Bio (NYSE:NUVB) Issues Earnings Results, Hits Expectations

Nuvation Bio (NYSE:NUVB) issued its earnings results on Monday. The company reported ($0.11) earnings per share for the quarter, hitting the consensus estimate of ($0.11), FiscalAI reports. Nuvation Bio had a negative net margin of 813.07% and a negative return on equity of 54.99%. The company had revenue of $41.87 million for the quarter, compared to analyst estimates of $36.82 million.

Here are the key takeaways from Nuvation Bio’s conference call:

• IBTROZI secured full FDA approval (June 11, 2025) and the launch shows strong early adoption—432 new patients started in 2025 (216 in Q4) at a pace ~6x faster than the two prior ROS1 TKI launches.
• Management highlights an unusually durable clinical profile for IBTROZI—pooled median duration of response of ~50 months in TKI‑naive patients and an 89% confirmed ORR—attributing potential intracranial control to measured TRKB inhibition while preserving tolerability.
• Financial and corporate progress includes Q4 total revenue of $41.9M (including milestones), IBTROZI net U.S. product revenue of $15.7M in Q4 ($24.7M for 2025), approximately $529M in cash and marketable securities, and substantial ex‑U.S. partnerships (ASI/Eisai) that provide upfront proceeds and milestone/royalty upside.
• Near‑term revenue growth lagged patient starts because the early launch mix was heavily weighted to later‑line patients who discontinue quickly, and management expects gross‑to‑net (~25% now) to rise slightly, which may constrain short‑term sales momentum.
• Safusidenib advancement—global phase 3 SIGMA trial in high‑risk/high‑grade IDH1 mutant glioma is enrolling with a 2029 readout and a separate grade‑3 oligodendroglioma cohort expected in 2027 that could support accelerated approval discussions if ORR is compelling.

Nuvation Bio Stock Performance

Shares of NUVB opened at $5.84 on Tuesday. Nuvation Bio has a 1 year low of $1.54 and a 1 year high of $9.75. The company’s 50 day simple moving average is $6.65 and its 200 day simple moving average is $5.53. The company has a market capitalization of $2.00 billion, a price-to-earnings ratio of -9.13 and a beta of 1.51. The company has a debt-to-equity ratio of 0.14, a quick ratio of 8.39 and a current ratio of 8.48.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in NUVB. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Nuvation Bio by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 108,547 shares of the company’s stock worth $191,000 after acquiring an additional 4,608 shares during the last quarter. Millennium Management LLC raised its position in shares of Nuvation Bio by 52.4% during the 1st quarter. Millennium Management LLC now owns 3,774,003 shares of the company’s stock worth $6,642,000 after purchasing an additional 1,298,131 shares during the period. Envestnet Asset Management Inc. bought a new stake in shares of Nuvation Bio in the 2nd quarter worth approximately $92,000. Creative Planning boosted its position in Nuvation Bio by 267.1% during the 2nd quarter. Creative Planning now owns 39,288 shares of the company’s stock valued at $77,000 after purchasing an additional 28,585 shares during the period. Finally, Cetera Investment Advisers acquired a new position in Nuvation Bio during the 2nd quarter valued at approximately $29,000. Hedge funds and other institutional investors own 61.67% of the company’s stock.

Wall Street Analyst Weigh In

NUVB has been the subject of several research analyst reports. Royal Bank Of Canada raised their price objective on Nuvation Bio from $9.00 to $12.00 and gave the company an “outperform” rating in a research note on Wednesday, January 21st. Truist Financial set a $13.00 price target on Nuvation Bio in a research note on Tuesday, January 27th. HC Wainwright lowered their price objective on shares of Nuvation Bio from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Monday, January 12th. B. Riley Financial began coverage on shares of Nuvation Bio in a research report on Wednesday, November 19th. They set a “buy” rating and a $12.00 target price for the company. Finally, UBS Group started coverage on shares of Nuvation Bio in a research report on Wednesday, January 7th. They issued a “neutral” rating and a $10.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Nuvation Bio currently has an average rating of “Moderate Buy” and a consensus price target of $11.67.

Trending Headlines about Nuvation Bio

Here are the key news stories impacting Nuvation Bio this week:

• Positive Sentiment: Company press release: Nuvation reported Q4 and full‑year 2025 results, highlighted 216 patient starts on IBTROZI in Q4 (432 since launch), a licensing & collaboration agreement with Eisai for Europe/other territories, positive Phase 2 safusidenib data, and $529.2M in cash and marketable securities — this combination of early commercial traction, partner expansion and strong liquidity is a key reason shares are rallying. Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Commercial outlook: Coverage on Nuvation’s first‑line IBTROZI strategy cites a 50‑month median duration of response (DOR) and expanding global partnerships — supports expectations for durable revenue growth if adoption continues. Nuvation Bio outlines first-line IBTROZI growth strategy
• Positive Sentiment: Earnings highlights: Call takeaways and coverage note “strong market acceptance” of IBTROZI (referred to as Erozi in some coverage) and management reiterated commercial momentum — helps explain investor bullishness. Nuvation Bio Inc (NUVB) Q4 2025 Earnings Call Highlights
• Positive Sentiment: Revenue beat: Coverage from Zacks notes Q4 revenue of $41.9M topped estimates while EPS (-$0.11) met consensus — revenue upside offsets some profitability concerns and is being treated positively by the market. Zacks: Nuvation Bio Inc. Reports Q4 Loss, Beats Revenue Estimates
• Neutral Sentiment: Earnings/transcript availability: The full Q4 2025 earnings transcript and the conference call are published (useful for analysts and investors digging into guidance and adoption details). Nuvation Bio (NUVB) Q4 2025 Earnings Transcript Seeking Alpha: Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Clinical protocol update: Nuvation amended the protocol for ongoing safusidenib trials in high‑risk/high‑grade IDH1‑mutant astrocytoma — a routine but constructive development for the program’s path forward. Nuvation Bio Amends Protocol on Safusidenib Trials
• Negative Sentiment: Profitability and margins remain a concern: Nuvation is still unprofitable (Q4 EPS in line at -$0.11; company reports a large negative net margin and negative ROE), and analysts expect continued losses for the year — this keeps valuation risk elevated despite commercial progress. MarketBeat: Nuvation Bio Q4 Results & Call

About Nuvation Bio

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.